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SoOBJECTIVES This study sought to determine whether splenic activation after acute coronary syndrome (ACS) is linked
to leukocyte proinﬂammatory remodeling and whether splenic activity independently predicts the risk of cardiovascular
disease (CVD) events.
BACKGROUND Pre-clinical data suggest the existence of a cardiosplenic axis, wherein activation of hematopoietic
tissues (notably in the spleen) results in liberation of proinﬂammatory leukocytes and accelerated atherosclerotic
inﬂammation. However, it is presently unknown whether a cardiosplenic axis exists in humans and whether splenic
activation relates to CVD risk.
METHODS 18F-ﬂuorodeoxyglucose (18FDG)–positron emission tomography (PET) imaging was performed in 508 indi-
viduals across 2 studies. In the ﬁrst study, we performed FDG-PET imaging in 22 patients with recent ACS and 22 control
subjects. FDG uptake was measured in spleen and arterial wall, whereas proinﬂammatory gene expression of circulating
leukocytes was assessed by quantitative real-time polymerase chain reaction. In a second study, we examined the
relationship between splenic tissue FDG uptake with subsequent CVD events during follow-up (median 4 years) in
464 patients who previously had undergone FDG-PET imaging.
RESULTS Splenic activity increased after ACS and was signiﬁcantly associated with multiple indices of inﬂammation:
1) up-regulated gene expression of proinﬂammatory leukocytes; 2) increased C-reactive protein; and 3) increased arterial
wall inﬂammation (FDG uptake). Moreover, in the second study, splenic activity (greater than or equal to the median)
was associated with an increased risk of CVD events (hazard ratio [HR]: 3.3; 95% conﬁdence interval [CI]: 1.5 to 7.3;
p ¼ 0.003), which remained signiﬁcant after adjustment for CVD risk factors (HR: 2.26; 95% CI: 1.01 to 5.06; p ¼ 0.04)
and for arterial FDG uptake (HR: 2.68; 95% CI: 1.5 to 7.4; p ¼ 0.02).
CONCLUSIONS Our ﬁndings demonstrate increased splenic metabolic activity after ACS and its association with
proinﬂammatory remodeling of circulating leukocytes. Moreover, we observed that metabolic activity of the spleen
independently predicted risk of subsequent CVD events. Collectively, these ﬁndings provide evidence of a cardiosplenic
axis in humans similar to that shown in pre-clinical studies. (J Am Coll Cardiol Img 2015;8:121–30) © 2015 by the
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SUV = standardized uptake
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122P atients remain at an increased riskfor recurrent cardiovascular disease(CVD) events in the weeks to months
after an acute coronary syndrome (ACS)
(1,2); however, the pathophysiological basis
for this increased risk remains unclear. Pre-
clinical studies have shown that proliferation
of monocyte progenitors and proinﬂamma-
tory activation of monocytes within the he-
matopoietic tissues (i.e., bone marrow [BM]
and spleen) may play an important role in
accelerating atherosclerosis after myocardial
infarction (3,4). Pre-clinical studies demon-
strated that after myocardial infarction in
mice, monocyte progenitor cells departed
BM niches, which resulted in ampliﬁed
extramedullary monocytopoiesis (3). The
observation of activation of the inﬂamma-
tory cell milieu and the migration of proin-
ﬂammatory monocytes from spleen to heart
in animal models of heart failure (5) have
given rise to the concept of a cardiosplenicaxis. Recently, the concept of a cardiosplenic axis
has been extended to stable atherosclerosis in murine
models as well (6); however, it is presently unknown
whether such an axis exists in humans.SEE PAGE 131Imaging with 18F-ﬂuorodeoxyglucose-positron emis-
sion tomography (FDG-PET) provides a noninvasive
measure of tissue glycolysis (7) and is used clinically
for the evaluation of tumors (8) and infectious foci (9).
The biological basis for FDG accumulation within
mononuclear inﬂammatory cells lies in the fact that
macrophages have a high metabolic rate (10), especially
after proinﬂammatory activation (11,12), and hence
avidly accumulate FDG (13). Additionally, cellular
accumulation of FDG is increased in rapidly prolifer-
ating cells (14). Because in animal models of myocardial
infarction, splenic activation is marked by prolifera-
tion of monocyte progenitor cells and proinﬂam-
matory activation of monocytes (3,4), we sought to
evaluate splenic activation in humans using FDG PET/
computed tomography (CT) imaging. Furthermore, wessachusetts; and the zzDivision of Cardiology, Massachusetts Ge
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received April 17, 2014; revised manuscript received Septemberinvestigated whether splenic metabolic activity relates
to proinﬂammatory gene expression of circulating
leukocytes.
In the ﬁrst study, we tested the hypothesis that
the metabolic activity of hematopoietic tissues (i.e.,
BM and spleen) occurs in humans with recent ACS.
In the second study, and in a separate population,
we investigated whether the metabolic activity of
these hematopoietic tissues predicts the risk of sub-
sequent CVD events. To do so, we evaluated BM
and splenic metabolic activity, by FDG uptake, in a
group of individuals with no known atherosclerotic
disease who had undergone clinically indicated FDG-
PET/CT scans and for whom clinical follow-up data
were available. We then assessed whether the base-
line hematopoietic tissue FDG signal correlated with
arterial wall inﬂammation and independently pre-
dicted the subsequent development of incident CVD
events.
METHODS
OVERALL STUDY SCHEMA. We performed 2 separate
studies (Figure 1). The ﬁrst study, the ACS study, was
designed to test the hypothesis that metabolic activ-
ity of the hematopoietic tissues of BM and spleen was
more prominent after ACS and was associated with
levels of serum proinﬂammatory biomarkers, proin-
ﬂammatory gene expression of circulating leuko-
cytes, and arterial wall inﬂammation. To test these
hypotheses, 44 patients were prospectively recruited
at Massachusetts General Hospital. FDG-PET/CT im-
aging was performed in all subjects, and FDG uptake
was assessed in the BM, spleen, arterial wall, and
control tissues. Additionally, serum biomarker assays
and quantitative real-time polymerase chain reaction
of proinﬂammatory gene expression in circulating
leukocytes was performed.
The second study, the clinical outcomes study, was
conducted in a separate population and was designed
to test the hypothesis that hematopoietic tissue (BM
and spleen) metabolic activity was associated with
arterial wall inﬂammation and independently pre-
dicted the subsequent risk of incident CVD events. Toneral Hospital and Harvard Medical School, Boston,
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In the ﬁrst study (A), 22 post–acute coronary syndrome (ACS) patients underwent 18F-ﬂuorodeoxyglucose–positron emission tomography/computed tomography
(FDG-PET/CT) imaging within 10 days of their event. We compared bone marrow, splenic, and arterial activity in these patients with 22 sex-matched control subjects. In
the second study (B), we studied 464 subjects who had undergone FDG-PET/CT imaging for various clinical indications and assessed whether bone marrow and splenic
activity were associated with future cardiovascular disease (CVD) events. PAD ¼ peripheral artery disease; TIA ¼ transient ischemic attack.
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123test these hypotheses, we evaluated BM and splenic
activity (using FDG PET/CT imaging) in 464 in-
dividuals consecutively identiﬁed from a database of
patients who had undergone clinically indicated FDG-
PET/CT scans. Thereafter, the development of incident
CVD events was adjudicated by blinded cardiol-
ogists, and the relationship between hematopoietic
tissue activity and subsequent CVD risk was assessed.
STUDY SUBJECTS. Study 1: ACS Study. Forty-four
subjects were prospectively recruited into this study.
Twenty-two people with ACS (ACS group) and 22
without recent ACS (control group) were recruited
(Figure 1A).
The ACS group was identiﬁed according to pre-
speciﬁed criteria. Eligible patients were adults (age
38 to 69 years) with recent ACS (deﬁned as myocar-
dial infarction or unstable angina documented by
electrocardiogram, cardiac enzymes, or angiogram)
who were clinically stable and able to undergo an
FDG-PET/CT scan within 10 days of the incident
CVD event. The control group consisted of 22 people
with documented clinical atherosclerotic disease
who were sex-matched to the ACS group. The control
group underwent contemporaneous FDG-PET/CT
imaging and was selected among male or femalesubjects, 35 to 80 years of age, with documented
clinical atherosclerotic disease (i.e., coronary artery
disease, peripheral arterial disease, or carotid dis-
ease) but no history of ACS within the previous
6 months. Exclusion criteria for both groups in-
cluded systemic chronic inﬂammatory conditions,
type I diabetes mellitus or fasting plasma glucose
>175 mg/dl, presence of severe heart failure or severe
left ventricular dysfunction, or signiﬁcant radiation
exposure within the preceding 12 months. Addition-
ally, individuals were excluded from participation
if they had recent evidence of cardiogenic shock,
sustained ventricular tachyarrhythmia, or hypoxemia
(deﬁned as O2 saturation <90% or requirement for
>2 l/min supplemental oxygen to maintain O2 satu-
ration >90%).
Study 2: Clinical Outcomes Study. Using a retrospec-
tive study design, 464 people who underwent prior
PET/CT imaging at the Massachusetts General Hos-
pital between 2005 and 2008 were included in this
analysis (Figure 1B). We included everyone with
PET/CT images of chest and abdomen who met the
following pre-deﬁned inclusion criteria: 1) either
absence of prior cancer diagnosis or remission from
cancer at the time of PET imaging and throughout
FIGURE 2 Increased Bone Marrow, Spleen, and Arterial FDG Uptake After ACS
Coronal views of aorta (left) and bone marrow (middle) and axial view of spleen (right). 18F-ﬂuorodeoxyglucose (FDG) uptake was signiﬁcantly
increased in the arterial wall (aorta), bone marrow, and spleen in patients with acute coronary syndrome (ACS) versus control subjects.
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124the follow-up period; 2) age $30 years; 3) no prior
history of CVD; and 4) absence of acute or chronic
inﬂammatory or autoimmune disease (on the basis of
documented medical history) or use of chronic anti-
inﬂammatory therapy. Subjects were required to
have at least 3 clinical visit notes (spanning $1 year)
to ensure availability of sufﬁcient clinical data and
to determine clinical status at the time of PET imaging.
FDG-PET/CT IMAGING. FDG-PET/CT imaging was
performed using previously reported reproducible
and validated approaches (15). Brieﬂy, 18F-FDG was
administered intravenously (approximately 10 mCi
for a 70-kg patient) after an overnight fast, and im-
aging was performed 90 min after FDG injection with
PET/CT.
IMAGE ANALYSIS. While investigators were blinded
to all clinical and temporal data, images were analyzed
at a central core laboratory at Massachusetts General
Hospital using Leonardo TrueD software (Siemens,
Forchheim, Germany). Arterial inﬂammation was
measured within pre-deﬁned sections of the 3
target vessels (right and left carotid artery and aortic
wall) using previously validated methods (Online
Appendix) (15,16). BM FDG uptake was measured by
placing a region of interest over axial sections of
individual vertebrae from T1 to L5. The maximum
standardized uptake value (SUVmax) for each vertebra
was recorded, and BM activity was calculated as the
mean of SUVmax of all vertebrae in the imaging ﬁeld.
Similarly, splenic FDG uptake was assessed by placingregions of interest in 3 orthogonal planes (axial,
sagittal, and coronal planes) (Online Figure 1). SUV-
max was recorded in each plane, and splenic activity
was calculated as the mean of SUVmax values of the 3
planes. Intrareader reproducibility for measurement
of BM FDG uptake was determined as intraclass cor-
relation coefﬁcient of 0.99 (p < 0.001), and percent
variance was calculated as 2.2  2.1%. Reproducibility
for splenic FDG uptake measurement was determined
as intraclass correlation coefﬁcient of 0.96 (p < 0.001),
and percent variance was calculated as 4.7  3.8%.
For evaluations of the correlation of FDG uptake be-
tween tissues (within patients), we additionally used
uncorrected SUVs to avoid the contribution that
a common background value would make to the
relationship.
GENE EXPRESSION ASSAYS. Inﬂammatory gene
expression was assessed by quantitative real-time
polymerase chain reaction of peripheral blood leu-
kocyte proinﬂammatory mRNA. (Please see the
Online Appendix for details about assessment of
inﬂammatory gene expression.)
ADJUDICATION OF CVD EVENTS. Events were clini-
cally adjudicated by 2 cardiologists who were blinded
to all imaging data. Using clinically available records,
incident CVD events included ischemic stroke or
transient ischemic attack, ACS, revascularization
(coronary, carotid, or peripheral), unstable angina,
heart failure, or CVD death. (Please see the Online
Appendix for additional details.)
TABLE 1 Baseline Characteristics of ACS Study Subjects
ACS Patients
(n ¼ 22)
Control Subjects
(n ¼ 22) p Value
Age (yrs) 58  8.5 62  10 0.19
Male 16 (72) 16 (72) 0.63
Current smoker 9 (41) 3 (14) 0.04
Diabetes mellitus 4 (18) 3 (14) 0.50
Hypertension 17 (77) 18 (82) 0.50
BMI (kg/m2) 31.5  5.6 29.2  3.4 0.16
Baseline values (mg/dl)
Total cholesterol 173.2  38.2 159.8  21.9 0.21
LDL cholesterol 95.1  31.6 92.8  18.5 0.80
HDL cholesterol 42.8  12.7 53.1  16.2 0.03
Triglycerides 174.2  94.6 120.4  42.1 0.04
FDG uptake*
Bone marrow 2.9  0.5 2.4  0.6 0.01
Spleen 2.6  0.6 2.1  0.3 0.03
Arterial wall 2.7  1.2 2.2  0.6 0.04
Control tissues
Subcutaneous adipose tissue 0.16  0.05 0.17  0.06 0.57
Pectoralis muscle 0.41  0.07 0.43  0.12 0.53
Values are mean  SD or n (%). *FDG uptake in bone marrow, spleen, and control tissues
is reported as standardized uptake value, whereas arterial FDG uptake is reported as TBR.
ACS ¼ acute coronary syndrome; BMI ¼ body mass index; FDG ¼ 18F-ﬂuorodeoxyglucose;
LDL ¼ low-density lipoprotein; HDL ¼ high-density lipoprotein; SUV ¼ standardized uptake value;
TBR ¼ target-to-background ratio.
TABLE 2 Relationship Between Hematopoietic Tissue Activity and Inﬂammatory
Biomarkers
Bone Marrow FDG Uptake Spleen FDG Uptake
Correlation Coefﬁcient p Value Correlation Coefﬁcient p Value
Serum biomarkers
CRP 0.62 0.002 0.44 0.04
TNF 0.19 0.46 0.39 0.44
IL-1b 0.43 0.09 0.37 0.47
Gene expression in leukocytes
CD36 0.05 0.85 0.51 0.03
MSR-1 0.53 0.02 0.48 0.04
S100A9 0.15 0.54 0.59 0.01
TLR-2 0.19 0.45 0.45 0.06
Bone marrow and spleen FDG uptakes were analyzed as standardized uptake value. Correlation coefﬁcients
represent Spearman r. Correlations were assessed in the entire population (n ¼ 44) including both post–acute
coronary syndrome patients and control subjects. In analyses that were limited to the subgroups, we did not
observe signiﬁcant correlations except for between S100A9 expression and splenic activity in the control group
(r ¼ 0.8, p ¼ 0.02).
CRP ¼ C-reactive protein; FDG ¼ 18F-ﬂuorodeoxyglucose; IL ¼ interleukin; MSR ¼ macrophage scavenger
receptor; TLR-2 ¼ toll-like receptor 2; TNF ¼ tumor necrosis factor.
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125STATISTICAL ANALYSIS. Descriptive data are pre-
sented as mean  SD for continuous parametric vari-
ables, median (interquartile range) for continuous
nonparametric data, and frequency with proportions
for nominal variables as appropriate. An independent
samples Student t test was used for cross-sectional
comparison of normally distributed continuous vari-
ables (such as BM, spleen, and arterial FDG uptake)
between the ACS and control groups. AMann-Whitney
U test was used for the similar analyses of continuous
variables without normal distribution (such as C-
reactive protein [CRP]). Fisher exact test was per-
formed for comparison of dichotomous variables.
Pearson correlation coefﬁcient (R) was used to assess
correlations between continuous variables once
normal distribution was veriﬁed, and Spearman r was
reported as correlation coefﬁcient for non-normally
distributed variables. For comparison of means, 95%
conﬁdence intervals (CIs) are provided. Kaplan-
Meier estimates of the proportions of patients free
from CVD events were stratiﬁed separately, by me-
dian FDG uptake in spleen and BM (SUVmax). Cox
proportional hazards regression was used to calcu-
late hazard ratios (HRs) and 95% CIs. Framingham
Risk Score (FRS) was not normally distributed
among the study subjects, so we converted it to an
ordinal variable (low [<10], intermediate [10 to 20],
and high risk [>20]) and used the ordinal variable
for the analyses. Two-tailed p values are reported
and statistical signiﬁcance was deﬁned as p < 0.05.
All statistical analyses were performed with SPSS
version 22 (IBM, Armonk, New York).
RESULTS
STUDY 1: ACS STUDY. Baseline characteristics. There
were no signiﬁcant differences between ACS and
control subjects for age or major CVD risk factors
except for current smoking (p ¼ 0.04). All the people
in the control group had documented clinically diag-
nosed CAD. Baseline patient characteristics and de-
mographics are summarized in Table 1. Additional
information on clinical presentations of ACS patients
is detailed in Online Table 1.
Hematopoietic tissue metabolic activity is up-regulated
after ACS. We observed a signiﬁcantly higher splenic
FDG uptake in individuals with recent ACS (SUV, 2.6
 0.6 vs. 2.1  0.3; p ¼ 0.03). Similarly, BM FDG up-
take was substantially higher in ACS patients than
in control subjects (SUV, 2.9  0.5 vs. 2.4  0.6; p ¼
0.01) (Figure 2). In contrast, FDG uptake in control
tissues (subcutaneous adipose tissue [SAT] and pec-
toralis muscles) was not increased in ACS patients
compared with control subjects (SAT SUV, 0.16  0.05vs. 0.17  0.06; p ¼ 0.57; pectoralis muscle SUV, 0.41
 0.07 vs. 0.43  0.12; p ¼ 0.53) (Table 1).
Hematopoietic tissue metabolic activity correlates with
CRP and proinﬂammatory gene expression in leukocytes.
Serum CRP concentrations were signiﬁcantly higher
in the ACS group than in control subjects (median
[interquartile range]: 7.70 [1.45 to 21.2] vs. 2.47 [1.00
to 4.13]; p ¼ 0.04). In addition, CRP correlated with
BM FDG uptake (r ¼ 0.62, p ¼ 0.002) and splenic FDG
TABLE 3 Baseline Ch
Age (yrs)
Male
Current smoker
Hypertension
Diabetes mellitus
Statin use
BMI (kg/m2)
Dyslipidemia
Baseline values (mg/dl
Total cholesterol
LDL cholesterol
HDL cholesterol
Triglycerides
FRS*
<10
10-20
>20
FDG uptake†
Bone marrow
Spleen
Arterial wall
Subcutaneous adipos
Values are mean  SD, med
data to calculate FRS. †FDG
whereas arterial FDG uptak
BMI ¼ body mass index;
Score; HDL ¼ high-density
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126uptake (r ¼ 0.44, p ¼ 0.04). There was a strong cor-
relation between CRP and BM FDG uptake (r ¼ 0.66,
p ¼ 0.02) in post-ACS patients, whereas no signiﬁcant
correlation was observed in control subjects (r ¼
0.48, p ¼ 0.13). Furthermore, we observed a signiﬁ-
cant correlation between hematopoietic tissue FDG
uptake and the expression of several genes associated
with proinﬂammatory activation within circulating
leukocytes (Table 2).
Relationships with arterial inﬂammation. As expected,
the mean arterial FDG uptake (target to background
ratio [TBR]) was greater in patients with ACS than in
control subjects (2.7  1.2 vs. 2.2  0.6; p ¼ 0.04)
(Table 1). Moreover, BM and splenic metabolic
activity (SUV) signiﬁcantly correlated with arterial
inﬂammation (TBR; r ¼ 0.34, p ¼ 0.03 and r ¼ 0.46,
p ¼ 0.01 for BM and spleen, respectively). Similarly,
the uncorrected arterial FDG signal (SUV) also corre-
lated with BM and splenic SUV (r ¼ 0.67, p < 0.001
and r ¼ 0.37, p ¼ 0.04 for BM and spleen, respec-
tively). In contrast, FDG uptake in the control tissues
did not correlate with FDG uptake in the arterial wall
(r ¼ 0.11, p ¼ 0.39 and r ¼ 0.20, p ¼ 0.10 for the arterial
wall vs. SAT and pectoralis muscle, respectively).aracteristics of the Clinical Outcomes Study
Full Cohort
(n ¼ 464)
Individuals Without
Subsequent CVD
(n ¼ 430)
Individuals With
Subsequent CVD
(n ¼ 34) p Value
55 (44-46) 54 (44-65) 66 (60-78) <0.001
201 (43) 186 (43) 15 (44) 0.53
46 (10) 36 (8.5) 10 (29) 0.001
158 (34) 139 (32) 19 (56) 0.006
41 (9) 34 (8) 7 (20) 0.02
89 (19) 75 (17) 14 (41) 0.002
26 (23-31) 26 (23-31) 27 (24-32) 0.33
127 (27) 112 (26) 15 (44) 0.02
)
192  45 193  45 184  41 0.32
111  38 112  32 107  34 0.49
56  18 57  19 50  14 0.04
124  72 121  72 140  71 0.18
186 (82) 168 (85) 18 (60) 0.08
36 (16) 24 (12) 12 (40) <0.001
5 (2) 5 (2.5) 0 (0) 0.68
2.2 (1.9-2.6) 2.2 (1.9-2.6) 2.4 (2.1-2.8) 0.03
2.1 (1.8-2.4) 2.1 (1.8-2.3) 2.2 (2.1-2.5) 0.01
1.9 (1.8-2.2) 1.9 (1.8-2.2) 2.2 (1.9-2.3) <0.001
e tissue 0.17 (0.14-0.2) 0.16 (0.14-0.2) 0.19 (0.13-0.22) 0.28
ian (interquartile range), or n (%). *A subset of 227 subjects provided all the required
uptake in bone marrow, spleen, and subcutaneous adipose tissue is reported as SUV
e is reported as TBR.
CVD ¼ cardiovascular disease; FDG ¼ 18F-ﬂuorodeoxyglucose; FRS ¼ Framingham Risk
lipoprotein; LDL ¼ low-density lipoprotein.Additionally, we observed a signiﬁcant correlation
between arterial inﬂammation (TBR) and CRP (r ¼
0.45, p ¼ 0.04). Arterial inﬂammation (TBR) was
associated with mRNA levels of CD16 and toll-like
receptor (TLR)-4 in the peripheral leukocytes such
that tertiles of mean arterial TBR correlated with
mRNA levels of CD16 (r ¼ 0.47, p ¼ 0.04) and TLR-4
(r ¼ 0.49, p ¼ 0.03).
STUDY 2: CLINICAL OUTCOMES STUDY. Baseline
characteristics. In the second study, we evaluated 464
participants with follow-up for 6.5 years (median,
4 years). A total of 34 individuals developed CVD
events (2 per 100 person-years at risk) during this
period. Baseline characteristics and demographics
are presented in Table 3. Additional information on
baseline cancer and cancer treatment status of “clin-
ical outcome” subjects is detailed in Online Table 2.
CVD events. The events were characterized as follows:
8 ACS (6 acute myocardial infarction and 2 unstable
angina), 8 coronary revascularizations, 7 strokes,
2 transient ischemic attacks, 2 carotid endarterec-
tomies, 4 cases of new-onset angina (1 with and 3
without obstructive disease documented on coronary
catheterization), 2 new diagnoses of peripheral arte-
rial disease, 2 peripheral revascularizations secondary
to peripheral artery disease, and 1 subsequent death
due to acute myocardial infarction. The distribution
of events between men and women was not statisti-
cally signiﬁcant (15 men and 19 women, p ¼ 0.54).
Hematopoietic tissue activity correlates with arterial
inﬂammation. BM metabolic activity (FDG uptake)
signiﬁcantly correlated with arterial SUV (r ¼ 0.56,
p < 0.001) (Figure 3A) and background-corrected
arterial TBR (r ¼ 0.22, p < 0.001). Similarly, splenic
activity signiﬁcantly correlated with arterial SUV
(r ¼ 0.79, p < 0.001) (Figure 3B) and arterial TBR (r ¼
0.23, p < 0.001). Additionally, we observed a strong
positive correlation between BM and splenic activa-
tion (r ¼ 0.71, p < 0.001). In contrast, there was no
signiﬁcant correlation between SAT metabolic activ-
ity and arterial inﬂammation (r ¼ 0.074, p ¼ 0.11).
BM and splenic activation are associated with subsequent
risk of CVD events. Patients with higher BM activity
(greater than or equal to the median) had an in-
creased risk for subsequent CVD events (HR: 2.15;
95% CI: 1.05 to 4.41; p ¼ 0.04) (Figure 4A). However,
in a Cox regression model, the association was no
longer signiﬁcant after adjusting for FRS (p ¼ 0.12),
statin use (p ¼ 0.06), or arterial FDG uptake (p ¼ 0.14).
In contrast, splenic FDG uptake (greater than
or equal to the median) was associated with an
increased risk for CVD events (HR: 3.3; 95% CI: 1.5
to 7.3; p ¼ 0.003) (Figure 4B), which remained sig-
niﬁcant after adjustment for CVD risk factors of age,
FIGURE 3 Correlation Between FDG Uptake in Bone Marrow, Spleen, and Arterial Wall
In the clinical outcomes study, a strong correlation between baseline arterial 18F-ﬂuorodeoxyglucose (FDG) uptake with (A) bone marrow and
(B) spleen was observed. SUV ¼ standardized uptake value.
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127male sex, smoking (HR: 2.25; 95% CI: 1.01 to 5.04;
p ¼ 0.04) and also after adjustment for hypertension,
diabetes mellitus, and dyslipidemia (HR: 2.76; 95%
CI: 1.24 to 6.18; p ¼ 0.01). In 2 additional models,
the association between splenic FDG uptake and
CVD events remained signiﬁcant after adjustment
for FRS (HR: 2.9; 95% CI: 1.2 to 6.9; p ¼ 0.01) and
after adjustment for statin use (HR: 2.8; 95% CI: 1.3
to 6.4; p ¼ 0.01).
The association between higher splenic activity
and risk for CVD events remained signiﬁcant after
adjustment for history of prior cancer diagnosis,
chemotherapy, and radiotherapy (HR: 3.37; 95% CI:
1.5 to 7.4; p ¼ 0.003), after adjustment for time from
chemotherapy to imaging (HR: 2.65; 95% CI: 1.03 to
6.78; p ¼ 0.04), after the exclusion of subjects with a
history of lymphoma and hematologic malignancies
(HR: 3.4; 95% CI: 1.4 to 8.4; p ¼ 0.008), and after the
exclusion of subjects with a prior history of any type
of cancer (HR: 5.1; 95% CI: 1.1 to 23.8; p ¼ 0.04). In
addition, we observed similar ﬁndings after adjust-
ment for arterial TBR (HR: 2.68; 95% CI: 1.5 to 7.4;
p ¼ 0.02). In contrast, metabolic activity in the
control tissue (SAT) was not associated with risk of
cardiovascular events (HR: 1.26; 95% CI: 0.64 to 2.48;
p ¼ 0.50) (Figure 4C).
DISCUSSION
We observed that BM and splenic tissue metabolic ac-
tivity increased substantially after ACS and correlated
with CRP level and expression of proinﬂammatory
markers of circulating leukocytes.We also observed, in
a separate study group, that splenic tissue activity was
independently associated with an increased risk ofCVD events in people without known atherosclerosis.
These data suggest that in humans, BM and splenic
activity are associated with an increase in proin-
ﬂammatory mediators, which may play a role in
increased atherosclerotic plaque inﬂammation and
an elevated risk of subsequent CVD events.
INFLAMMATION IN ATHEROSCLEROSIS. Inﬂammation
plays a central role in the pathogenesis of athero-
sclerosis and its associated clinical complications
(17). The response to acute ischemic injury is believed
to trigger a molecular and cellular systemic inﬂam-
matory response whereby the recruitment of proin-
ﬂammatory leukocytes results in deleterious effects
on the blood vessel wall (18). Numerous mediators
contribute to this process, including chemokines,
cytokines, proteases, and adhesion molecules, and
their interactions contribute to atherosclerotic plaque
instability (19). Although statins appear to reduce
vascular risk by favorably modifying this biology (20),
a substantial residual risk remains; thus, there exists
a strong impetus to further our knowledge of the
underlying pathobiology of atherosclerosis (21).
METABOLIC ACTIVITY OF SPLEEN AND PRO-
INFLAMMATORY REMODELING OF LEUKOCYTES. Our
data suggest that after ACS, increased metabolic ac-
tivity of hematopoietic tissue (especially spleen), as
assessed by FDG-PET, may represent an early step in
a process that results in proinﬂammatory remodeling
of leukocytes (especially monocytes). This concept is
supported by our observation that CRP, a marker of
systemic inﬂammation, was strongly correlated to BM
and splenic activity. These ﬁndings are consistent
with those of Kim et al. (22). Moreover, in the current
study, we have extended the observations of Kim
FIGURE 4 Proportion Free of CVD Events Stratiﬁed by Bone Marrow, Spleen, and SAT Metabolic Activity
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Individuals with higher (greater than or equal to median) (A) bone marrow activity (18F-ﬂuorodeoxyglucose [FDG] uptake) and (B) splenic
activity at baseline had an increased risk for cardiovascular disease (CVD) events. Baseline subcutaneous adipose tissue (SAT) activity did not
predict CVD events in individuals stratiﬁed into higher versus lower FDG values. (C) p Value from Kaplan-Meier survival curve was derived from
log-rank test.
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128et al. (22) by providing novel data on the gene
expression of proinﬂammatory leukocytes and by
evaluating the association between splenic activity
and subsequent CVD events. We showed that the
gene expression of circulating proinﬂammatory
monocytes (i.e., MSR-1 [macrophage scavenger re-
ceptor-1] [23,24], S100A9 [25], CD36 [24], interleukin-
1b and TLR-4 [26]) was signiﬁcantly correlated with
BM and splenic activity. It is notable that proin-
ﬂammatory gene activation within circulating leuko-
cytes was more closely associated with metabolic
activity of the spleen than it was for the BM. Several
reasons may account for this observation. First,
although the BM is an important and steady source of
circulating leukocytes, the spleen acts as a large
reservoir and may contribute substantially to the pool
of circulating leukocytes after myocardial infarction
(27). Second, the spleen has been shown to be animportant locus of myeloid cell production in animal
models of atherosclerosis and myocardial infarction
(3). Hence, the activation state of the spleen (more
than the BM) may closely relate to the proin-
ﬂammatory state of circulating leukocytes, especially
after injury or stress. Further studies are warranted to
explore the precise underlying mechanisms.
CARDIOSPLENIC AXIS. Both the BM and spleen may
be involved in a highly coordinated and dynamic
biological interaction with the vascular wall that
results in accelerated atherogenesis after ACS in
humans. In pre-clinical studies, the role of BM and
spleen activity after acute MI is established. Prior
pre-clinical studies support our ﬁndings in ACS
patients, demonstrating a paradigm in which BM-
and spleen-derived inﬂammatory cells provoke vas-
cular inﬂammation. Additionally, pre-clinical studies
have demonstrated that activation of inﬂammatory
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129mononuclear cells in spleen plays a central role in
progression of heart failure in response to cardiac-
derived alarmins, which further emphasizes the pre-
sence of interplay between cardiovascular system
and spleen–cardiosplenic axis (5). A recent autopsy
study of patients after myocardial infarction showed
that proinﬂammatory monocytes were depleted
from the BM and spleen but were increased in
atherosclerotic plaques, whereas the spleen experi-
enced a pronounced reduction of monocytes, which
suggests a prominent role of the spleen in trafﬁcking
monocytes to atherosclerotic plaques (28). The re-
sults of our clinical outcome study suggest that this
interconnection between the spleen and arterial wall
may be present in a stable setting as well.
In this study, we conﬁrmed in humans the
paradigm-shifting pre-clinical observation (3) that
BM and splenic activity occurs after ACS and is
associated with increased arterial wall inﬂammation.
It has been shown that apolipoprotein E–deﬁcient
mice that lack BM-derived progenitor cells or spleen
(3) have a reduction in atherosclerosis. In addition,
this study for the ﬁrst time raises the possibility that
residual risk in stable patients might also be related
to the spleen-atherosclerotic plaque axis. As such,
the results of our study may encourage the develop-
ment of novel therapeutic agents aimed at modu-
lating the activity of progenitor cells to attenuate the
systemic inﬂammatory milieu and its adverse clinical
sequelae. The study also highlights that splenic
metabolic activity may represent a novel target of
future therapies designed to minimize atheroscle-
rosis progression.
STUDY LIMITATIONS. Because of ethical concerns,
BM and splenic biopsy samples were not obtained
from patients, which limits histological correlation of
the FDG signal. Flow cytometry analysis of peripheral
blood leukocytes was not performed, thus limiting
evaluation of monocyte subsets. In addition, a large
proportion of patients with ACS (41% of the total
study population) presented with unstable angina,
and many did not have increased levels of cardiacbiomarkers. Hence, it is possible that in a population
with a greater degree of myocardial injury, BM and
splenic activation may be greater than what was
observed in the ACS population. In addition, the
design of this study precludes assessment of splenic
activity before ACS. Given the retrospective nature
of the clinical outcomes study and the fact that the
study population was drawn from a clinical database
that consisted primarily of cancer survivors, the
generalizability of the ﬁndings may be constrained.
Other confounding factors might include history and
type of cancer, as well as type of chemotherapy
or radiotherapy. Although we tried to minimize
the impact of these potential confounders through
statistical adjustments, we believe our ﬁndings war-
rant conﬁrmation in prospective studies. Lastly, al-
though we observed compelling interrelationships
between BM and splenic activation, leukocyte proin-
ﬂammatory gene expression, and arterial inﬂamma-
tion, we acknowledge that these relationships do
not necessarily indicate causality.
CONCLUSIONS
Our ﬁndings demonstrate that splenic metabolic ac-
tivity is increased after ACS and correlates with
proinﬂammatory remodeling of circulating leuko-
cytes. Furthermore, we show for the ﬁrst time that
splenic activity correlates with arterial inﬂammation
and is an independent predictor of the risk of incident
CVD events. These observations suggest that the
cardiosplenic axis may be clinically relevant in both
acute and stable atherosclerotic vascular disease and
provide impetus for further study of the mechanisms
underlying the link between the hematopoietic tis-
sues (BM and spleen) and progression of atheroscle-
rotic CVDs.
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